Validation of MASCC Score for Risk Stratification in Patients of Hematological Disorders with Febrile Neutropenia
- 1 October 2016
- journal article
- research article
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 33 (3) , 355-360
Abstract
The purpose of this study is to evaluate the association of MASCC score (Multinational Association for Supportive Care in Cancer Score) in patients with febrile neutropenia (as resultant treatment of hematological disorders) for risk assessment of morbidity and mortality. Patients presenting with Febrile Neutropenia from November 2011 till December 2013 were enrolled in the study. Initially all patients were hospitalized and their MASCC score was calculated, however those with high risk stayed in hospital till full ANC recovery while low risk group was discharged earlier and keenly followed as out-patient while being on prophylactic oral antibiotics. The MASCC risk-index score was calculated and patients with risk score >21 were regarded as low-risk while <21 were labeled as high-risk. On the basis of 226 febrile neutropenia patient 132(58.4 %) were categorized as low risk while 94(41.5 %) as high risk patients according to MASCC risk index score. In low risk group 123(93 %) had uncomplicated infection while 9(7 %) had complicated infections. There was no mortality documented in low risk group while eight patients died in high risk group. In this study we correctly predicted outcome of 123(93 %) low risk group patients. The study had positive predictive value of 93 % with both sensitivity and specificity of 65 and 75 % respectively. The MASCC risk score is a valuable tool in determining the outcome in patients with febrile neutropenia.Keywords
This publication has 11 references indexed in Scilit:
- Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic reviewCritical Reviews in Oncology/Hematology, 2014
- Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective studyExperimental and Therapeutic Medicine, 2011
- Executive Summary: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2011
- A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignanciesAnnals of Oncology, 2009
- Prevention and Treatment of Cancer-Related InfectionsJournal of the National Comprehensive Cancer Network, 2008
- Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patientsSupportive Care in Cancer, 2007
- Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patientsCancer, 2006
- Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index scoreSupportive Care in Cancer, 2004
- Epidemiology of Febrile NeutropeniaSupportive Cancer Therapy, 2003
- The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer PatientsJournal of Clinical Oncology, 2000